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homeostasis and is tightly regulated through the parathyroid hormone (PTH)/PTHrP receptor (PTH1R) signaling pathway. We investigated the role of PTH1R in the kidney by generating a mouse model with targeted deletion of PTH1R in the thick ascending limb of Henle (TAL) and in distal convoluted tubules (DCTs): Ksp-cre;Pth1r fl/fl . Mutant mice exhibited hypercalciuria and had lower serum calcium and markedly increased serum PTH levels. Unexpectedly, proteins involved in transcellular Ca 2+ reabsorption in DCTs were not decreased. However, claudin14 (Cldn14), an inhibitory factor of the paracellular Ca 2+ transport in the TAL, was significantly increased. Analyses by flow cytometry as well as the use of Cldn14-lacZ knock-in reporter mice confirmed increased Cldn14 expression and promoter activity in the TAL of Ksp-cre;Pth1r fl/fl mice. Moreover, PTH treatment of HEK293 cells stably transfected with CLDN14-GFP, together with PTH1R, induced cytosolic translocation of CLDN14 from the tight junction. Furthermore, mice with high serum PTH levels, regardless of high or low serum calcium, demonstrated that PTH/PTH1R signaling exerts a suppressive effect on Cldn14. We therefore conclude that PTH1R signaling directly and indirectly regulates the paracellular Ca 2+ transport pathway by modulating Cldn14 expression in the TAL. Finally, systemic deletion of Cldn14 completely rescued the hypercalciuric and lower serum calcium phenotype in Ksp-cre;Pth1r fl/fl mice, emphasizing the importance of PTH in inhibiting Cldn14. Consequently, suppressing CLDN14 could provide a potential treatment to correct urinary Ca 2+ loss, particularly in patients with hypoparathyroidism.
PTH1R | CLDN14 | mouse kidney | hypercalciuria | paracellular R enal calcium reabsorption is critical for maintaining systemic calcium homeostasis, and thus a failure in this process has severe health consequences (1) . Renal calcium leak is widely recognized as the most common metabolic abnormality in calcium stone formers (2, 3) , and it is also known to increase the risk of osteoporosis and fractures (4) (5) (6) . However, the mechanisms of renal calcium reabsorption, and, consequently, the pathogenesis of renal calcium leak, are not completely understood. For this reason, treatments to reduce urinary Ca 2+ excretion are still limited to dietary recommendations and thiazide diuretics (2, 3) .
Sixty-five percent of renal calcium reabsorption takes place in the proximal tubules (PTs) through a paracellular solvent-drag, nonregulated pathway, and 25% occurs in the thick ascending limb of Henle (TAL) through a regulated paracellular pathway. The remaining 10-15% of calcium reabsorption takes place in the distal convoluted tubules (DCTs) via active transcellular transport. In the TAL, the apical Na
− cotransporter and renal outer medullary K + channel generate a lumen-positive transepithelial potential difference that drives calcium reabsorption via the paracellular pathway (7, 8) . This process is controlled by specific tightjunction molecules belonging to the claudin family. Claudins are tetraspan proteins that form paracellular channels allowing selective permeation of ions through the epithelial tight junction. Claudin-16 (CLDN16) and CLDN19 assemble a heteromeric paracellular complex constituting either an intercellular pore or an ion concentration sensor to regulate paracellular reabsorption of cations in the TAL. Previously, CLDN14, which is mainly expressed in the TAL, was found to bind to CLDN16 and to inhibit its channel permeability (9) . CLDN14 thus acts as a negative gatekeeper for the heteromeric CLDN16/CLDN19 complex and modulates Ca 2+ reabsorption in the TAL, likely in response to dietary Ca 2+ load (8) . Although it is well known that mutations in human genes encoding CLDN16 and CLDN19 are responsible for familial hypomagnesemia with hypercalciuria and nephrocalcinosis (Online Mendelian Inheritance in Man 248250) (10, 11) , knowledge of the central role for CLDN14 in regulating renal paracellular calcium reabsorption emerged only few years ago. The key role of CLDN14 is supported by the striking observation that mice with global deletion of claudin14 (Cldn14
) show a failure in increase of urinary Ca 2+ excretion in response to a high-calcium diet (9) . In humans, a homozygous mutation in the CLDN14 gene on chromosome 21q22 causes autosomal recessive nonsyndromic deafness-29 (12) . More recently, CLDN14 polymorphisms have
Significance
Renal calcium reabsorption is a critical process for maintaining systemic calcium homeostasis. Although the role of parathyroid hormone (PTH) in the regulation of transcellular Ca 2+ reabsorption in distal convoluted tubules is well understood, its potential role in controlling the paracellular Ca 2+ transport in the thick ascending limb of Henle (TAL) has not been investigated. We now present data demonstrating that PTH/PTHrP receptor (PTH1R) signaling directly and indirectly controls the levels of Claudin14 (CLDN14), a tightjunction protein responsible for paracellular Ca 2+ transport in the TAL. Our findings suggest that down-regulation of Claudin14 could provide a potential treatment option to correct urinary Ca 2+ loss, particularly in patients with hypoparathyroidism.
also been associated with nephrolithiasis and low bone density, inferring a role for CLDN14 in the pathogenesis of renal calcium leak (13, 14) . Systemic calcium homeostasis is maintained by a well-coordinated regulation of renal calcium reabsorption; intestinal calcium absorption; and bone resorption by parathyroid hormone (PTH), 1,25(OH) 2 D, and extracellular calcium itself via the calciumsensing receptor (CaSR). PTH is secreted by the parathyroid glands in response to low serum calcium and vitamin D levels, and it stimulates calcium reabsorption, phosphate excretion, and the production of 1,25(OH) 2 D in the kidney and can also induce bone resorption to stimulate the release of calcium and phosphate from the skeleton (15) . It binds to and activates the PTH/PTHrP receptor (PTH1R), a G protein-coupled receptor that is expressed in many tissues but has its highest expression in kidney and bone (16) . PTH1R activates the adenylyl cyclase (cAMP), IP 3 , PKC, and Ca 2+ signaling pathways (17) . In the kidney, PTH regulates the expression and function of the transient receptor potential vanilloid 5 (TRPV5) and of Calbindin 28K, two important proteins responsible for transcellular Ca 2+ transport in the DCTs. This process has been extensively studied and is well understood (7) . However, a potential role for PTH signaling via the PTH1R in controlling the paracellular calcium transport in the TAL has not been investigated so far.
It has been shown that the CaSR is expressed in the TAL and that an acute inhibition of CaSR increases the permeability of the paracellular pathway to Ca 2+ , independent of PTH actions (18) . More recently, it has been discovered that CaSR regulates paracellular Ca 2+ transport by modulating the expression of Cdln14 (19, 20) . Expression of PTH1R has also been found in the TAL. However, due to its wide expression in the kidney, including the PT, TAL, and DCT (21) , specific actions of PTH in modulating paracellular Ca 2+ transport have not been identified. We therefore explored the role of PTH1R specifically in the distal parts of the nephron using a mouse model in which ablation of PTH1R was limited to the TAL, DCT, connecting tubule, and collecting duct (CD). Here, we report findings demonstrating that PTH1R signaling regulates paracellular Ca 2+ transport by directly and indirectly modulating the expression of Cldn14 in the TAL.
Results
Generation and Characterization of Ksp-cre;Pth1r fl/fl Mice. Mice with a specific Pth1r deletion in the distal parts of the nephron (TAL, DCT, connecting tubule, and CD) under the control of the Ksp promoter were generated using Cre-loxP recombination (Fig. S1  A and B) . We first examined the in vivo expression pattern of Cadherin-16 Cre (Ksp-cre) mice using Tomato reporter mice (Ksp-cre;Tomato fl/fl ) ( Fig. 1 A-C ). Our analyses demonstrate that Cadherin-16 promoter-driven expression of tdTomato is primarily limited to the TALs and DCTs in the kidney, with a small amount of expression found in the CDs ( Fig. 1 B and C) . No expression was detected in the glomeruli or proximal convoluted tubules (Fig. 1A) . We then confirmed efficient deletion of Pth1r in Ksp-cre;Pth1r fl/fl mice by quantitative RT-PCR (qRT-PCR) using whole-kidney RNA, where we detected a statistically significant reduction in expression (∼30%). We analyzed specific Pth1r deletion in the TAL by immune-isolating cells specific to the TAL with magnetic beads coupled to the Tamm-Horsfall protein antibody and observed a 75% reduction in Pth1r mRNA levels (Fig. 1D) . The marked decrease in the phospho-CREB (p-CREB) band for the mutants (Fig. 1E) demonstrates the efficient reduction of PTH1R downstream signaling. Ksp-cre;Pth1r fl/fl mice appeared macroscopically normal in size and weight and were indistinguishable from their control littermates ( Fig. S1 C and D) . Serum and urine samples from 6-wk-old mice were collected for analyses of biochemical parameters. Interestingly, mutant mice showed significantly decreased serum calcium levels, markedly elevated serum PTH levels, and severe hypercalciuria (Fig. 1F) . No major changes could be detected between Pth1r fl/fl and Ksp-cre;Pth1r fl/fl mice for serum phosphate (9.52 ± 0.49 vs. 9.74 ± 0.45 mg/dL, n = 5-6), intact and C-terminal FGF23 levels (intact: 366 ± 57 vs. 429 ± 46 pg/mL, n = 8-10; C-terminal: 715 ± 40 vs. 817 ± 77 pg/mL, n = 14-15), urea nitrogen (34.5 ± 4.3 vs. 29.1 ± 4.0 mg/dL, n = 7), or creatinine (0.47 ± 0.09 vs. 0.28 ± 0.07 mg/dL, n = 7). Also, no differences in urinary nitrogen (1,034 ± 44 vs. 1,038 ± 110 mg/dL, n = 5-6) and urinary creatinine (22.0 ± 2.9 vs. 23.5 ± 5.4 mg/dL, n = 5-6) could be detected. Moreover, renal gene expression of the vitamin D receptor (Vdr) and Klotho (Kl) was comparable between Pth1r fl/fl and Ksp-cre;Pth1r fl/fl mice (relative expression of Vdr: 1.00 ± 0.05 vs. 1.15 ± 0.04, relative expression of Kl: 1.00 ± 0.00 vs. 0.94 ± 0.03. Gene expression was normalized to Gapdh). Moreover, no major changes in serum 1,25(OH) 2 D levels could be detected in Ksp-cre;Pth1r fl/fl mice, which is in accordance with an unaltered expression of the 1α-hydroxylase and 24-hydroxylase, despite higher serum PTH levels (Fig. S1E) .
Expression of Genes Involved in Renal Calcium Transport. PTH1R signaling is critical for renal Ca 2+ reabsorption in DCTs, so the significant increase in urinary Ca 2+ was not unexpected. We then examined the expression of the well-known proteins responsible for transcellular Ca 2+ transport in the DCTs: TRPV5 and Calbindin D28k. Surprisingly however, a significant increase in Trpv5 and calbindin D28k mRNA and Calbindin D28k protein levels ( Fig. 2 A and B) could be observed in Ksp-cre;Pth1r fl/fl mice, suggesting that the renal calcium leak cannot have occurred in that part of the kidney. This provocative finding led us to investigate further whether loss of PTH1R in the TAL could possibly affect paracellular permeation of calcium in the TAL. We compared the expression pattern of Cldn14, Cldn16, and Cldn19 in Ksp-cre;Pth1r fl/fl and Pth1r fl/fl mice at 6 wk of age. Notably, we observed a greater than fivefold increase in basal Cldn14 mRNA expression in whole kidneys of mutants compared with Pth1r fl/fl littermates. Isolation of TAL-specific cells from control and mutant mice resulted in even higher expression levels of Cldn14. No apparent changes were found in Cldn16 or Cldn19 mRNA levels in either whole-kidney or TAL cells (Fig. 2C ). Western blot analyses confirmed an increase in Cldn14 protein expression in isolated TAL cells of Ksp-cre;Pth1r fl/fl mice and showed a slight decrease in Cldn16 and Cldn19 levels, suggesting that Cldn14 might control the Cldn16/Cldn19 complex (Fig. 2D ).
We were able to support our data further by showing an increase in Cldn14 expression in Ksp-cre;Pth1r fl/fl mice using flow cytometry of isolated TAL cells from Ksp-cre;Tomato Effects of PTH and High Serum Calcium Levels on Claudin14 Expression.
We next tested the effects of PTH in the presence of high serum calcium levels on Cldn14 expression by injecting 6-wk-old Pth1r
and Ksp-cre;Pth1r fl/fl mice with either vehicle (0.9% NaCl) or PTH (1-34) (50 nmol/kg of body weight). Serum and kidney samples were collected 2 h after treatment. As expected, PTH injection resulted in similar significant rises in serum calcium and 1,25(OH) 2 D levels in both genotypes. We also confirmed a marked increase in the expression of the 1α-hydroxylase, a well-known target gene of PTH, in the proximal convoluted tubules (PCTs) of both genotypes. This increased expression indicated a proper response to PTH and an intact function of PTH1R in portions of the kidney that are not affected by Cadherin-16 cre recombinase (Fig. 3A) .
Consistent with our previous findings, Cldn14 mRNA expression was markedly elevated (greater than fivefold) in mutant kidneys after vehicle (0.9% NaCl) injection compared with controls ( Fig. 3B ). PTH (1-34) injections did not affect Cldn14 mRNA levels in Pth1r fl/fl mice but did lead to a substantial up-regulation (>25-fold) of Cldn14 expression in Ksp-cre;Pth1r fl/fl without PTH1R in the TAL (Fig. 3B ). These results suggest a regulatory mechanism in which an induction of Cldn14 by high serum calcium is neutralized by suppression of Cldn14 by PTH, as observed in Pth1r fl/fl mice. However, in Ksp-cre;Pth1r fl/fl mice, where the suppressive functions of PTH are absent, high serum calcium can freely stimulate Cldn14 expression, resulting in markedly elevated Cldn14 levels.
Effects of Low Serum Calcium and High PTH Levels on Claudin14
Expression. We and others have found that Cldn14 is positively correlated with dietary Ca 2+ in that increased serum calcium levels lead to higher Cldn14 expression to promote Ca 2+ excretion (9) . On the other hand, reduced serum calcium levels result in suppression of Cldn14 to facilitate renal Ca 2+ reabsorption (22) . To determine whether deletion of PTH1R from the TAL disturbs this correlation, we challenged Pth1r fl/fl and Ksp-cre; Pth1r fl/fl mice by feeding them a Ca 2+ -deficient diet. Immediately after weaning, mice were fed either a 0% Ca or 0.6% Ca control diet for a period of 3 wk, and were then killed and analyzed at 6 wk of age. As expected, serum calcium levels were significantly reduced in both mouse lines when fed the Ca 2+ -deficient diet (Fig. 4A ). This reduction in serum calcium levels was accompanied by high serum PTH (Pth1r fl/fl : 1,675 ± 221 pg/mL and Kspcre;Pth1r fl/fl : 1,729 ± 183 pg/mL, n = 9) and 1,25(OH) 2 D levels.
Importantly, Cldn14 mRNA expression in Pth1r fl/fl mice was fully suppressed in response to both (i) the low serum calcium, and (ii) the high serum PTH levels compared with mice fed the control diet (Fig. 4B) . In contrast, Cldn14 expression in Ksp-cre; Pth1r fl/fl mice fed a Ca 2+ -deficient diet remained relatively high, and levels were comparable to the ones seen in control mice on the regular 0.6% calcium diet (Fig. 4B) . Although Cldn14 expression in Ksp-cre;Pth1r fl/fl mice was markedly reduced in response to low serum calcium, we believe that the remaining Cldn14 levels are due to the failure of PTH to suppress them in the absence of the PTH1R in the TAL. The failure in full suppression of Cldn14 in kidneys of Ksp-cre;Pth1r fl/fl mice implies that PTH can regulate Cldn14 expression independent of serum calcium levels. We also generated Casr −/− mice (22) as an alternative to feeding a Ca 2+ -deficient diet. These mice cannot sense calcium, and therefore fail to induce Cldn14. In addition, Casr −/− mice have high serum PTH levels, which further suppress Cldn14, resulting in total loss of Cldn14 expression (Fig. S2 A excretion (Fig. S2B) to preserve calcium. No significant changes in expression of Cldn16/19 were detected in any of these models (Fig. S2A) . Moreover, Trpv5 and calbindin D28k levels were largely unaltered upon low-calcium challenge, except for some increase in calbindin D28k in Ksp-cre;Pth1r fl/fl mice, which could be explained as a compensatory attempt to recover some calcium that was lost in the TAL due to the remaining presence of Cldn14 (Fig. S3) .
PTH Modulates Cldn14 Membrane Expression. We then investigated potential direct effects of PTH on claudin proteins by stably transfecting CLDN14-GFP, CLDN16-GFP, and CLDN19-GFP fusion proteins in HEK293 cells that also express human PTH1R. It has previously been reported that the tight-junction inhibitor sodium decanoate (C10) can alter the distribution of claudins, and thereby suppress the tight-junction barrier function (23, 24) . To test our cell system, we performed fluorescence analysis over a 2-to 3-h period and confirmed that C10 treatment immediately relieves the tight junction between cells and increases CLDN14 protein expression on the cell-cell junctions (Fig. S4 ). Subsequently, we tested the effects of PTH (1-34) on CLDN proteins in each of these cell lines. Time-lapse microscopy shows that PTH induces translocation of CLDN14, whereby the protein moves from discrete nodules on the cell membrane to a more even distribution along the cell membrane and also to the cytosol. PTH had no observable effect on CLDN16 or CLDN19 in this assay (Fig. 5A) . We further investigated the CLDN14 nodular structures on the cell-cell junction by generating 3D reconstruction images with serial z-stack optical sections. Fig. 5B (Left) shows 3D reconstitution images of CLDN14, CLDN16, and CLDN19 before and after 180 min of PTH treatment. Fig. 5B (Right) represents the quantification, with red and yellow colors indicating higher expression of CLDNs located on tight junctions and blue-shaded colors representing relatively lower claudin expression in the cytosol. Our results indicate that PTH treatment significantly altered the distribution of CLDN14 from thick nodular structures, presumably tight junctions, to a more diffuse, thin-lined structure and more CLDN14 signal in the cytosol (light blue in Fig. 5B, Right) . ). Cldn14 expression is limited to the inner ear and the TAL of the kidney, so loss of its function was not expected to result in any gross developmental defects. Cldn14 −/− mice challenged with a high-Ca 2+ diet have previously been shown to preserve calcium inadequately (9), so we anticipated that loss of its function in Ksp-cre;Pth1r fl/fl mice could rescue the observed calcium leak. We first confirmed the complete absence of Cldn14 in our double-mutant mouse models (Cldn14 ) as demonstrated by the undetectable mRNA levels in the kidney of these mice (Fig. 6A ) compared with controls (Pth1r fl/fl and Ksp-cre;Pth1r fl/fl mice). We then collected serum and urine, and measured urinary Ca 2+ excretion in all four genotypes. As anticipated, deletion of Cldn14 from Ksp-cre;Pth1r fl/fl mice was able to prevent the urinary Ca 2+ loss and restore levels comparable to the ones seen in control mice (Fig. 6B) . This finding provides evidence that the hypercalciuria in Ksp-cre;Pth1r fl/fl mice is primarily due to elevated Cldn14 expression and that PTH1R signaling in the TAL is critical to suppress Cldn14. The elimination of the calcium leak also corrected the lower serum calcium and higher PTH levels in Cldn14
fl/fl mice (Fig. 6C ).
Discussion
Maintenance of systemic calcium homeostasis is crucial and requires a constant regulation of various proteins involved in calcium sensing, intestinal Ca 2+ absorption, renal Ca 2+ reabsorption, and bone resorption. PTH is a well-established endocrine hormone involved in these processes, and any alterations in its own activity or in the function of its receptor, PTH1R, can lead to mineral disorders (25) (26) (27) . In this study, we demonstrate that loss of PTH1R specifically in the distal parts of the nephron results in hypercalciuria and slightly lower serum calcium levels in Ksp-cre; Pth1r fl/fl mice compared with control littermates. Pth1r fl/fl and Ksp-cre; Pth1r fl/fl mice had similar creatinine levels, indicating that the glomerular filtration rate was also similar. Taken together, the stable serum creatinine levels and the slight decrease in serum calcium in Ksp-cre;Pth1r fl/fl mice suggest that the observed urinary Ca 2+ leak is due to decreased renal calcium reabsorption rather than increased filtered calcium load. The calcium imbalance explains the elevated serum PTH levels in the mutant mice.
PTH has been shown to enhance transcellular renal Ca 2+ reabsorption by stimulating the expression of TRPV5 and Calbindin D28k (28, 29). Importantly, the higher activity and prolonged presence of TRPV5 at the apical membrane enhance calcium reabsorption in the DCT (29, 30). Although there is no doubt that PTH can regulate TRPV5, most of the experiments were performed more than 7 y ago and the findings are predominantly based on in vitro experiments using cell cultures (29-32). In our study using an in vivo model, Ksp-cre;Pth1r fl/fl mice did not show the anticipated decline in levels of Trpv5 and calbindin D28k, but rather presented with elevated mRNA and/or protein levels. Although we did not directly measure Ca 2+ transport in the different segments of the tubule, these findings suggest that the observed urinary Ca 2+ loss is not primarily due to a failure in transcellular calcium transport in the DCT and imply that PTH might exert additional regulatory functions in other segments of the kidney, such as the TAL. In fact, we could demonstrate a significant increase in Cldn14 mRNA and protein expression associated with tight junctions in the TAL upon loss of PTH1R. This finding is consistent with the presence of a CREB response element in the mouse Cldn14 promoter, located between −100 and −111 bp (chromosome 16: 94008935-94008946) from the transcriptional start site (NM_019500, https://genome. ucsc.edu/). CLDN14 has been described to act as a negative gatekeeper for the heteromeric CLDN16/CLDN19 complex to modulate Ca 2+ reabsorption in the TAL; thus, an increase in CLDN14 would be expected to result in renal calcium leak. Also, polymorphisms in human CLDN14 have recently been associated with nephrolithiasis (13, 14) , and global Cldn14 −/− mice fail to excrete urinary Ca 2+ efficiently when needed (9). We therefore believe that the slight increase in Trpv5 and calbindin 28K could reflect a compensatory mechanism as an attempt to preserve calcium in DCTs that was lost in the TAL of Ksp-cre;Pth1r fl/fl mice. Such a process could be initiated by the high urinary Ca 2+ load that is sensed by either the conventional CaSR pathway or another calcium sensor expressed at the apical membrane of the DCT cells (33, 34) . Another explanation could be that the transcellular calcium transport in the DCTs is stimulated by the slightly increased serum calcitriol levels (35) . Of course, we cannot exclude the possibility that some PTH1R-positive cells are still expressed in DCTs, and could therefore mediate these actions. If such is the case, however, the small remaining amount of PTH1R is not sufficient to compensate fully for the renal calcium leak.
We also discovered a direct posttranslational effect of PTH on CLDN14 by developing a cell culture model with cells coexpressing PTH1R and CLDN14. We found that PTH treatment disrupted the proper, patchy membranous expression of CLDN14 and induced cytosolic translocation. Interestingly, PTH did not alter the membranous expression pattern of CLDN16 or CLDN19 in corresponding cell lines. These findings are consistent with posttranslational regulation of CLDN14 by PTH1R signaling without directly affecting CLDN16 or CLDN19. The reduced Cldn16 and Cldn19 protein levels observed in Ksp-cre;Pth1r fl/fl mice are likely an indirect effect resulting from the high Cldn14 levels in these mice. One possible mechanism for CLDN14 posttranslational regulation by PTH is the phosphorylation of CLDN14 and/or PDZ proteins [e.g., zonula occludens-1 (ZO-1), , which can bind to CLDN14. This hypothesis is consistent with previous studies reporting that the serine 217 in the carboxyl terminus of CLDN16 was phosphorylated by PKA to regulate the CLDN16-ZO-1 (tight-junction molecule-ZO-1) interaction required to maintain the tight junction (36) . Other protein modifications initiated by PTH1R signaling could be responsible as well. It has been reported that CLDN14 delocalization was related to mutation of membrane-proximal cysteines in the second and fourth transmembrane domains, which are possible palmitoylation sites. However, the palmitoylation mutant CLDN14 remained concentrated at sites of cell-cell contact and was competent to assemble into freeze-fracture strands when expressed in fibroblasts (37) . This result suggests that CLDN14 palmitoylation is important for efficient localization into tight junctions but not for stability or strand assembly. Because we observed that PTH treatment decreased CLDN14 on the cell-cell junction and induced its cytosolic translocation, PTH might directly modulate CLDN14 modification sites (e.g., palmitoylation) in the stable cell line, and this action could contribute to the regulation of renal Ca 2+ reabsorption in vivo. However, further experiments are needed to identify the mechanisms responsible for the posttranslational regulation of CLDN14 by PTH definitively and to determine potential CLDN14 binding partners associated with PTH1R signaling. Taken together, our in vivo and in vitro data demonstrate that PTH modulates CLDN14 levels and subcellular localization through transcriptional and posttranslational mechanisms, highlighting that CLDN14 is a key target for PTH to maintain proper renal Ca 2+ reabsorption in the TAL.
Research has shown that Cldn14 is regulated by calcium via the CaSR expressed in the TAL (19, 20, 22) . We have confirmed that loss of CaSR in mice results in decreased expression of Cldn14, in turn, resulting in decreased urinary Ca 2+ excretion (Fig. S2) . This finding provides additional evidence that low serum calcium levels reduce Cldn14 and thereby promote renal Ca 2+ reabsorption. PTH is the major regulator of systemic calcium homeostasis, so we explored whether PTH regulates Cldn14 via a calcium-dependent mechanism only or whether PTH can affect Cldn14 regardless of serum calcium levels. We analyzed the effects of high serum PTH in the presence of either high serum calcium (Fig. 3) or low serum calcium (Fig. 4) levels. First, we found that PTH (1-34) injection resulted in high serum calcium levels in control and mutant mice (Fig. 3) . However, only mutant mice responded with a marked increase (>25-fold) in Cldn14 expression. PTH1R is absent in these mice, so the elevation in Cldn14 levels can only be explained by an induction by high serum calcium (Fig. 7D) . Interestingly, Pth1r fl/fl mice did not show any changes in Cldn14, indicating that the presence of the PTH1R in the TAL of control mice can neutralize the effects of high serum calcium by suppressing Cldn14 levels (Fig. 7C) .
Second, feeding mice a low-calcium diet resulted in comparable low serum calcium and high serum PTH levels in both Pth1r fl/fl and Ksp-cre;Pth1r fl/fl mice. It is important to note that Cdn14 expression in control mice was completely abolished as expected (Fig.  7E) . In contrast, the very high basal Cldn14 levels in Ksp-cre; Pth1r fl/fl mice were decreased, yet levels remained significantly higher and were similar to the ones found in control mice on a normal diet (Fig. 7F) . These data infer that in control mice, both low serum calcium and high PTH inhibited Cldn14 levels. The same result was also observed in Casr −/− mice (Fig. S2A) . Ksp-cre; Pth1r fl/fl mice are resistant to PTH actions in the TAL, so only low serum calcium could effectively inhibit Cldn14 expression. These findings provide firm evidence that PTH modulates the function of Cldn14 regardless of serum calcium levels. We propose that this dual role of PTH provides a system to fine-tune renal calcium reabsorption in the TAL and that calcium reabsorption in DCTs adds another level of control to assure a tight regulation of renal calcium handling. Not only did we investigate the interaction of PTH and calcium levels in regulation claudin14 but we also looked for a potential role for vitamin D, which is an important regulator of calcium-reabsorbing proteins such as Trpv5 and Calbindin 28K (38) . We observed that a Ca 2+ -deficient diet resulted in lower Cldn14 mRNA expression in the presence of lower serum calcium and higher serum 1,25(OH) 2 D levels. On the other hand, PTH injections induced high serum calcium and 1,25(OH) 2 D levels, but Cldn14 mRNA expression remained unchanged. This observation clearly excludes active vitamin D as a regulator of Cldn14 and strongly suggests that only the CaSR pathway, together with PTH, is responsible for the modulation of Cldn14 expression (Fig. 7 A-F) . The final proof for this hypothesis would be to generate mice with deletion of both Casr and Pth1r in renal tubules, which could be the focus of a follow-up study.
Finally, we could demonstrate that genetic deletion of Cldn14 from Ksp-cre;Pth1r fl/fl mice was able to rescue their hypercalciuric phenotype and normalize the slightly lower serum calcium levels.
This finding provides firm evidence that in the absence of PTH1R signaling in the TAL, the unregulated expression of Cldn14 is responsible for the observed urinary Ca 2+ loss. Therefore, PTH/ PTH1R signaling plays a significant role in directly suppressing Cldn14 to counterbalance the opposing and stimulating effects of calcium on Cldn14 expression. We have shown that this dual function of PTH to (i) induce Cldn14 expression via increasing serum calcium and (ii) suppress Cldn14 regardless of serum calcium levels is critical to assure proper urinary Ca 2+ reabsorption in the TAL.
In conclusion, our study demonstrates a function for PTH/PTH1R signaling in the regulation of paracellular calcium transport in the TAL. We provide compelling biological evidence that PTH1R signaling can directly and indirectly regulate Cldn14. We also demonstrate that CLDN14 is a direct target of PTH transcriptional and posttranslational regulation. Moreover, we show that PTH can indirectly modulate Cldn14 via changing serum calcium levels via a , and CLDN19 and PTH1R at 0, 60, 120, and 180 min after PTH (1-34) treatment. Cells were placed on a 35-mm, no. 1.5 glass-bottomed culture dish for 2 d before imaging. Time-lapse microscopy was performed using a VivaView incubator fluorescence microscope. CLDN14-GFP is clearly visible as nodular structures on the cell-cell junction at 0 min. PTH treatment discomposed this structure over time into a weaker and more linear expression pattern along the cell membrane. No major changes were observed for CLDN16-GFP and CLDN19-GFP proteins. (B) Three-dimensional reconstruction images with serial z-stack optical sections. (Left) Three-dimensional reconstitution images of CLDN14, CLDN16, and CLDN19 before and after 180 min of PTH treatment. (Right) Quantification, with red and yellow colors indicating higher expression of claudins located on tight junctions and blue-shaded colors representing relatively lower claudin expression in the cytosol. PTH treatment significantly altered the distribution of CLDN14 from a thick nodular structure to a thin lined structure. The cytosolic CLDN14 diffuse pattern was increased by PTH treatment (light blue). The quantification is shown by box-and-whisker plots. PTH treatment significantly decreased tight-junction (TJ) CLDN14 and increased cytosolic CLDN14 (n = 16). ***P < 0.001 vs. 0 min on tight junction; † † † P < 0.001 vs. 0 min in cytosol.
CaSR-dependent pathway. A recent genome-wide association study of circulating PTH levels using 29,155 participants discovered five loci that were associated with variation in PTH levels. Notably, a robust association implicated CLDN14, the gene encoding Claudin-14. This finding further underscores the important connection between claudin-14 and PTH, even on a population level (39) . Defects in CLDN14 function have been implicated with hypercalciuria and nephrolithiasis (40) . However, the regulation of this paracellular transport pathway has not been fully understood, hindering the development of therapies to correct calcium reabsorption abnormalities in diseases. Our findings suggest that CLDN14 down-regulation could provide a potential treatment to correct urinary Ca 2+ loss in humans, especially in the presence of low serum PTH levels as found in patients with hypoparathyroidism.
Materials and Methods
Animals. Mice with renal tubule-specific PTH1R deletion were generated using the Cre-loxP recombination system as previously described (41, 42) . In brief, loxP sequences were introduced into the flanking regions of exon 1 of the Pth1r gene. Floxed mice were crossed with Ksp-cre transgenic mice [B6.Cg-Tg(Cdh16-cre)91Igr/J; The Jackson Laboratory] in which Cre recombinase expression is driven by the cadherin 16 promoter (Fig. S1A) . (9) . In the targeted allele, a lacZ cassette is expressed under the Cldn14 promoter. Animals expressing Cre recombinase driven by the protamine 1 promoter [129S/Sv-Tg(Prm-cre)58Og/J] were obtained from The Jackson Laboratory. These mice were crossed with our conditional Casr fl/+ mice (22) to generate germline Casr-deficient (Casr −/− ) mice. Genotypes were determined by PCR and electrophoresis (Fig. S1B ). Mice were fed a standard chow containing 0.81% calcium and 0.6% phosphorus (5058 LabDiet; Lab Supply). Low-calcium diet studies were performed using calcium-deficient and control diets. The calcium-deficient diet contained 0% calcium and 0.4% phosphorus based on American Institute of Nutrition, Research Diets (AIN-93) . The control calcium diet contained 0.6% calcium and 0.4% phosphorus. Mice were fasted for 4 h before blood and urine collection. All studies performed were approved by the Institutional Animal Care and Use Committee of the Harvard Medical School.
Biochemical Analyses. Blood was obtained by cheek pouch puncture. Urine was gathered by spot collection using 1.7-mL polystyrene tubes. Total serum calcium and phosphorus levels as well as urinary Ca 2+ , phosphorus, nitrogen, and creatinine levels were determined using Stanbio LiquiColor Kits (Stanbio Laboratory). Serum intact and C-terminal FGF23, PTH, and 1,25(OH) 2 RNA Isolation and Transcript Analyses. Total RNA was collected from wholekidney or renal TAL cells using TRIzol reagent (Life Technologies) according to the manufacturer's protocol. For qRT-PCR, cDNA was prepared using the QuantiTect Reverse Transcription Kit (Qiagen) and analyzed with FastStart Universal SYBR Green Master (ROX; Roche) in the StepOnePlus RealTime PCR System (Applied Biosystems) using specific primers designed for each targeted gene. Relative expression was calculated using the 2 -ΔΔCT method by normalizing with Gapdh housekeeping gene expression and presented as the fold increase relative to control.
Western Blotting. To test Cldn14, Cldn16, Cldn19, Trpv5, Calbindin D28k, and p-CREB expression in kidney and renal TAL cells, half of the kidney or isolated TAL cells were homogenized with radioimmunoprecipitation assay buffer (Alfa Aesar) with phosphatase and protease inhibitor mixture tablets (Roche) and centrifuged at 14,000 × g. The supernatant was then transferred to a fresh tube. Protein samples were heated with NuPAGE LDS Sample buffer (4×) (Life Technologies) and NuPAGE Reducing Agent (10×) (Life Technologies) at 70°C for 10 min, and were then subjected to NuPAGE 4-12% Bis-Tris SDS/PAGE using precast gels (Invitrogen) and NuPAGE MES SDS running buffer (Life Technologies). The separated proteins were transferred to iBlot Gel Transfer Stacks PVDF (Life Technologies) via an IBlot Gel Transfer Device (Life Technologies). After incubation in blocking solution, the PVDF membranes were treated with diluted rabbit anti-Cldn14, Cldn16, and Cldn19 (laboratory-generated); rabbit anti-Trpv5 (CAT21-A; Alpha Diagnostic); mouse anti-Calbindin-D28k (Sigma); rabbit anti-phospho-p44/42 (Thr202/ Tyr204; Cell Signaling Technology, Inc.); rabbit anti-Creb phosphor-Ser133 (Assay Biotechnology); or mouse β-actin (Sigma). Horseradish peroxideconjugated anti-rabbit or mouse IgG was used as the secondary antibody (Jackson ImmunoResearch Laboratories), and signal was detected by Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).
Immunofluorescence. Kidney tissues were dissected, fixed in 10% neutralized formalin, and embedded in paraffin or optimal cutting temperature compound (Sakura, Inc.). Five-micrometer sections were blocked with 0.1% BSA, 0.02% saponin, and 5% normal serum from species matching the labeled secondary antibodies. Sections were incubated with primary antibodies at 4°C overnight. Alexa Fluor-conjugated secondary antibodies were used for immunofluorescence visualization (Life Technologies). The primary antibodies were rabbit antiTamm-Horsfall Glycoprotein (BTI), rabbit anti-Cldn14 (laboratory-generated), rabbit anti-Aquaporin 2 (Novus Biologicals LLC), fluorescein-labeled Lotus tetragonolobus Lectin (LTL; Vector), rabbit anti-Trpv5 (CAT21-A; Alpha Diagnostic), mouse anti-Calbindin-D28k (Sigma), and rabbit anti-RFP (Rockland). Cells were cultured in DMEM with 10% FBS, 4.5 g/L D-glucose, 584 mg/L L-glutamine, 110 mg/L sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL streptomycin. Transient transfections were performed using PolyJet In Vitro DNA Transfection Reagent (SignaGen Laboratories) according to the manufacturer's protocol. After geneticin selection, DsRed and GFP double-positive cells were sorted by a FACSAria cell sorter (Becton Dickinson), collected in new tubes, and cultured in regular culture media. Cells were placed on 35-mm, no. 1.5 glassbottomed culture dishes (In Vitro Scientific) for 2 d before imaging. Time-lapse microscopy was performed using a VivaView incubator fluorescence microscope (Olympus). Z-stack serial images were obtained by means of an Olympus FV1200 laser confocal microscope. Three-dimensional reconstruction, look-up table, and surface plot analyses were performed using ImageJ software (NIH) to investigate tight-junction protein localization on cell-cell junctions.
Statistical Analyses. All statistical analyses were performed using GraphPad Prism 5 for Windows (GraphPad Software, Inc.). Variables were -deficient diet) (E) CaSR responds to low serum calcium levels by lowering its usual induction of Cldn14 expression to preserve Ca 2+ reabsorption. Low serum calcium levels also lead to a rise in serum PTH levels, which additionally suppress Cldn14, resulting in further conservation of calcium. (F) Loss of PTH1R signaling eliminates the suppression of Cldn14 by PTH, thereby leaving some Cldn14 expression intact.
tested by either a two-tailed t test or Tukey test. Values were expressed as mean ± SEM unless otherwise stated. A P value <0.05 was considered significant.
